Sionna Therapeutics announced it is laying off about 46% of its workforce as it reorients following an unexpected cystic fibrosis trial failure reported last month. The company said the cost and program reset accompany a strategic effort to find a path forward after the add-on program’s miss. The move highlights how quickly development-stage companies can be forced into operational triage when clinical outcomes do not match expectations—particularly in closely watched CF programs with defined time horizons. For investors and partners, Sionna’s staffing reduction suggests the near-term focus will shift toward reassessment of scientific strategy and resource allocation while keeping its broader platform goals under review.